Table 1 Two-sided (one-sided) type I error and power of the single and composite GPC analyses in 5000 permuted samples of the original EBS trial. The blister outcome indicates if a subject has a 40% reduction in blisters
From: Composite endpoints, including patient reported outcomes, in rare diseases
| Â | Type I error | Power |
|---|---|---|
| Â | Unmatched GPC | |
Single blister | 0.0692 (0.0216) | 0.5904 (0.7202) |
Single QoL | 0.0514 (0.0486) | 0.8642 (0.9302) |
Multi Prioritized | 0.0514 (0.0510) | 0.9594 (0.9812) |
Multi Non-prioritized | 0.0490 (0.0524) | 0.9886 (0.9716) |
| Â | Matched GPC | |
Single Blister | 0.0348 (0.0632) | 0.4751 (0.6029) |
Single QoL | 0.0422 (0.0610) | 0.7044 (0.8650) |
Multi Prioritized | 0.0260 (0.0258) | 0.5824 (0.8210) |